Logo image of AGL

AGILON HEALTH INC (AGL) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:AGL - US00857U1079 - Common Stock

0.7346 USD
+0.01 (+1.96%)
Last: 12/12/2025, 1:23:05 PM
Fundamental Rating

3

AGL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 100 industry peers in the Health Care Providers & Services industry. While AGL seems to be doing ok healthwise, there are quite some concerns on its profitability. AGL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

AGL had negative earnings in the past year.
In the past year AGL has reported a negative cash flow from operations.
In the past 5 years AGL always reported negative net income.
In the past 5 years AGL always reported negative operating cash flow.
AGL Yearly Net Income VS EBIT VS OCF VS FCFAGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

AGL's Return On Assets of -19.32% is on the low side compared to the rest of the industry. AGL is outperformed by 80.00% of its industry peers.
AGL's Return On Equity of -100.78% is on the low side compared to the rest of the industry. AGL is outperformed by 76.00% of its industry peers.
Industry RankSector Rank
ROA -19.32%
ROE -100.78%
ROIC N/A
ROA(3y)-12.12%
ROA(5y)-15.09%
ROE(3y)-35.05%
ROE(5y)-76.94%
ROIC(3y)N/A
ROIC(5y)N/A
AGL Yearly ROA, ROE, ROICAGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

AGL has a Gross Margin of 0.51%. This is amonst the worse of the industry: AGL underperforms 82.00% of its industry peers.
AGL's Gross Margin has declined in the last couple of years.
AGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 0.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.21%
GM growth 5Y-16.16%
AGL Yearly Profit, Operating, Gross MarginsAGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

5

2. Health

2.1 Basic Checks

AGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGL has been increased compared to 1 year ago.
AGL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AGL has an improved debt to assets ratio.
AGL Yearly Shares OutstandingAGL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AGL Yearly Total Debt VS Total AssetsAGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of 1.56, we must say that AGL is in the distress zone and has some risk of bankruptcy.
AGL has a Altman-Z score of 1.56. This is in the lower half of the industry: AGL underperforms 63.00% of its industry peers.
AGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.56
ROIC/WACCN/A
WACC9.23%
AGL Yearly LT Debt VS Equity VS FCFAGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

AGL has a Current Ratio of 1.08. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
AGL's Current ratio of 1.08 is on the low side compared to the rest of the industry. AGL is outperformed by 66.00% of its industry peers.
A Quick Ratio of 1.08 indicates that AGL should not have too much problems paying its short term obligations.
AGL has a worse Quick ratio (1.08) than 60.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 1.08
AGL Yearly Current Assets VS Current LiabilitesAGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500M 1B

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.85% over the past year.
Looking at the last year, AGL shows a quite strong growth in Revenue. The Revenue has grown by 9.94% in the last year.
Measured over the past years, AGL shows a very strong growth in Revenue. The Revenue has been growing by 50.14% on average per year.
EPS 1Y (TTM)3.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.9%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y48.96%
Revenue growth 5Y50.14%
Sales Q2Q%-1.08%

3.2 Future

AGL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.30% yearly.
AGL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.12% yearly.
EPS Next Y-21.58%
EPS Next 2Y15.33%
EPS Next 3Y16.71%
EPS Next 5Y15.3%
Revenue Next Year-3.86%
Revenue Next 2Y-0.29%
Revenue Next 3Y3.32%
Revenue Next 5Y8.12%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AGL Yearly Revenue VS EstimatesAGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B 8B 10B
AGL Yearly EPS VS EstimatesAGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8 -1

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGL Price Earnings VS Forward Price EarningsAGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGL Per share dataAGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

AGL's earnings are expected to grow with 16.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.33%
EPS Next 3Y16.71%

0

5. Dividend

5.1 Amount

No dividends for AGL!.
Industry RankSector Rank
Dividend Yield N/A

AGILON HEALTH INC

NYSE:AGL (12/12/2025, 1:23:05 PM)

0.7346

+0.01 (+1.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-23 2026-02-23/amc
Inst Owners68.68%
Inst Owner Change-3.95%
Ins Owners1.92%
Ins Owner Change-0.46%
Market Cap304.55M
Revenue(TTM)5.89B
Net Income(TTM)-308.46M
Analysts55.2
Price Target1.03 (40.21%)
Short Float %6.8%
Short Ratio2.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-91.76%
Min EPS beat(2)-114.66%
Max EPS beat(2)-68.86%
EPS beat(4)1
Avg EPS beat(4)56.59%
Min EPS beat(4)-114.66%
Max EPS beat(4)422.51%
EPS beat(8)3
Avg EPS beat(8)6.64%
EPS beat(12)4
Avg EPS beat(12)-1.81%
EPS beat(16)4
Avg EPS beat(16)-22.58%
Revenue beat(2)0
Avg Revenue beat(2)-3.16%
Min Revenue beat(2)-6.13%
Max Revenue beat(2)-0.19%
Revenue beat(4)1
Avg Revenue beat(4)-1.49%
Min Revenue beat(4)-6.13%
Max Revenue beat(4)0.91%
Revenue beat(8)2
Avg Revenue beat(8)-1.54%
Revenue beat(12)6
Avg Revenue beat(12)0.25%
Revenue beat(16)10
Avg Revenue beat(16)0.78%
PT rev (1m)-28.09%
PT rev (3m)-49.12%
EPS NQ rev (1m)-18.74%
EPS NQ rev (3m)-36.44%
EPS NY rev (1m)-24.42%
EPS NY rev (3m)-18.01%
Revenue NQ rev (1m)-0.54%
Revenue NQ rev (3m)-0.34%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)-0.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.05
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS14.2
BVpS0.74
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.32%
ROE -100.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 0.51%
FCFM N/A
ROA(3y)-12.12%
ROA(5y)-15.09%
ROE(3y)-35.05%
ROE(5y)-76.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.21%
GM growth 5Y-16.16%
F-Score4
Asset Turnover3.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 164.16%
Cap/Sales 0.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 1.08
Altman-Z 1.56
F-Score4
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)186.26%
Cap/Depr(5y)133.4%
Cap/Sales(3y)0.87%
Cap/Sales(5y)0.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.9%
EPS Next Y-21.58%
EPS Next 2Y15.33%
EPS Next 3Y16.71%
EPS Next 5Y15.3%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y48.96%
Revenue growth 5Y50.14%
Sales Q2Q%-1.08%
Revenue Next Year-3.86%
Revenue Next 2Y-0.29%
Revenue Next 3Y3.32%
Revenue Next 5Y8.12%
EBIT growth 1Y-8.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.15%
EBIT Next 3Y22.92%
EBIT Next 5Y19.5%
FCF growth 1Y32.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.25%
OCF growth 3YN/A
OCF growth 5YN/A

AGILON HEALTH INC / AGL FAQ

What is the ChartMill fundamental rating of AGILON HEALTH INC (AGL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to AGL.


What is the valuation status for AGL stock?

ChartMill assigns a valuation rating of 0 / 10 to AGILON HEALTH INC (AGL). This can be considered as Overvalued.


What is the profitability of AGL stock?

AGILON HEALTH INC (AGL) has a profitability rating of 0 / 10.


Can you provide the financial health for AGL stock?

The financial health rating of AGILON HEALTH INC (AGL) is 5 / 10.


What is the expected EPS growth for AGILON HEALTH INC (AGL) stock?

The Earnings per Share (EPS) of AGILON HEALTH INC (AGL) is expected to decline by -21.58% in the next year.